Dhaval Chauhan1, Ashwin B Karanam2, Aurelie Merlo3, P A Tom Bozzay4, Mark J Zucker5, Harish Seethamraju5, Nazly Shariati5, Mark J Russo6. 1. Department of Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey; Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey. Electronic address: dhavalchauhan86@gmail.com. 2. Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey; Newark Beth Israel Medical Center, Barnabas Heart Hospitals, Newark, New Jersey. 3. Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey. 4. Division of Pediatric and Congenital Cardiothoracic Surgery, Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 5. Newark Beth Israel Medical Center, Barnabas Heart Hospitals, Newark, New Jersey. 6. Department of Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey; Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey; Newark Beth Israel Medical Center, Barnabas Heart Hospitals, Newark, New Jersey.
Abstract
BACKGROUND: Lung transplantation is a widely accepted treatment for patients with end-stage lung disease related to idiopathic pulmonary fibrosis (IPF). However, there are conflicting data on whether double lung transplant (DLT) or single lung transplant (SLT) is the superior therapy in these patients. The purpose of this study was to determine whether actuarial post-transplant graft survival among IPF patients concurrently listed for DLT and SLT is greater for recipients undergoing the former or the latter. METHODS: The United Network for Organ Sharing provided de-identified patient-level data. Analysis included lung transplant candidates with IPF listed between January 1, 2001 and December 31, 2009 (n = 3,411). The study population included 1,001 (29.3%) lung transplant recipients concurrently listed for DLT and SLT, all ≥18 years of age. The primary outcome measure was actuarial post-transplant graft survival, expressed in years. RESULTS: Among the study population, 433 (43.26%) recipients underwent SLT and 568 (56.74%) recipients underwent DLT. The analysis included 2,722.5 years at risk, with median graft survival of 5.31 years. On univariate (p = 0.317) and multivariate (p = 0.415) regression analyses, there was no difference in graft survival between DLT and SLT. CONCLUSIONS: Among IPF recipients concurrently listed for DLT and SLT, there is no statistical difference in actuarial graft survival between recipients undergoing DLT vs SLT. This analysis suggests that increased use of SLT for IPF patients may increase the availability of organs to other candidates, and thus increase the net benefit of these organs, without measurably compromising outcomes.
BACKGROUND: Lung transplantation is a widely accepted treatment for patients with end-stage lung disease related to idiopathic pulmonary fibrosis (IPF). However, there are conflicting data on whether double lung transplant (DLT) or single lung transplant (SLT) is the superior therapy in these patients. The purpose of this study was to determine whether actuarial post-transplant graft survival among IPF patients concurrently listed for DLT and SLT is greater for recipients undergoing the former or the latter. METHODS: The United Network for Organ Sharing provided de-identified patient-level data. Analysis included lung transplant candidates with IPF listed between January 1, 2001 and December 31, 2009 (n = 3,411). The study population included 1,001 (29.3%) lung transplant recipients concurrently listed for DLT and SLT, all ≥18 years of age. The primary outcome measure was actuarial post-transplant graft survival, expressed in years. RESULTS: Among the study population, 433 (43.26%) recipients underwent SLT and 568 (56.74%) recipients underwent DLT. The analysis included 2,722.5 years at risk, with median graft survival of 5.31 years. On univariate (p = 0.317) and multivariate (p = 0.415) regression analyses, there was no difference in graft survival between DLT and SLT. CONCLUSIONS: Among IPF recipients concurrently listed for DLT and SLT, there is no statistical difference in actuarial graft survival between recipients undergoing DLT vs SLT. This analysis suggests that increased use of SLT for IPF patients may increase the availability of organs to other candidates, and thus increase the net benefit of these organs, without measurably compromising outcomes.
Authors: Francis T Delaney; John G Murray; Barry D Hutchinson; Jim J Egan; Michelle Murray; Sara Winward; Nicola Ronan; Carmel G Cronin Journal: Eur Radiol Date: 2022-06-16 Impact factor: 5.315
Authors: Andrew Rasky; David M Habiel; Susan Morris; Matthew Schaller; Bethany B Moore; Sem Phan; Steven L Kunkel; Martin Phillips; Cory Hogaboam; Nicholas W Lukacs Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-11-20 Impact factor: 5.464
Authors: Michael S Mulligan; David Weill; R Duane Davis; Jason D Christie; Farhood Farjah; Jonathan P Singer; Matthew Hartwig; Pablo G Sanchez; Daniel Kreisel; Lorraine B Ware; Christian Bermudez; Ramsey R Hachem; Michael J Weyant; Cynthia Gries; Jeremiah W Awori Hayanga; Bartley P Griffith; Laurie D Snyder; Jonah Odim; J Matthew Craig; Neil R Aggarwal; Lora A Reineck Journal: J Thorac Cardiovasc Surg Date: 2018-08-18 Impact factor: 5.209